Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
LLY News
Guggenheim raised the firm’s price target on Eli Lilly (LLY) to $948 from $875 and keeps a Buy rating on the shares. Following checks with IR and the firm’s U.S...
Peter Marks, the former head of vaccine regulation at the FDA, has joined Eli Lilly (LLY) to lead its molecule discovery and infectious disease programs, Lizzy...
Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our Twin Momentum Investor m...
Analyst ratings
77%
of 31 ratingsMore LLY News
New data from Eli Lilly (LLY) showed Omvoh is the first and only interleukin-23p19 to help patients with moderately to severely active ulcerative colitis achiev...
Eli Lilly and Co. (NASDAQ:LLY) plans to invest over $1 billion in India to strengthen its manufacturing network, according to Reuters. The move aims to tap int...
...
Eli Lilly is riding a big trend. Eli Lilly (LLY 1.15%) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand f...
Eli Lilly and Co. plans to invest more than $1 billion in India over the next few years to build new contract manufacturing capabilities in the South Asian nati...
Steve Scala, an analyst from TD Cowen, reiterated the Buy rating on Eli Lilly & Co. The associated price target remains the same with $960.00. Elevate Your Inv...
Eli Lilly (LLY) plans to invest more than $1B in India in the coming years to boost manufacturing and supply through local drugmakers, Reuters’ Rishika Sadam re...